Rapport Therapeutics Inc (RAPP)
Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for central nervous system disorders. Its lead candidate, RAP-219, is an investigational compound designed to inhibit TARPy8-containing AMPARs with picomolar affinity and is being studied for focal epilepsy, as well as other CNS indications such as peripheral neuropathic pain and bipolar disorder. The company is also advancing nicotinic acetylcholine receptor programs, including an a6 nAChR program for chronic pain and migraine and an a9a10 nAChR program for hearing and vestibular disorders. Founded in 2022, the company was previously known as Precision Neuroscience NewCo, Inc. and adopted its current name in October 2022. Rapport Therapeutics is headquartered in Boston, Massachusetts, and its common stock is listed on NASDAQ under the ticker RAPP.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-RAPP
|
$29.60
|
-29.7% Downside
|
Overvalued
|
$56.73
|
34.6% Upside
|
Undervalued
|
Good
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-18.8x
|
4.3x
|
100.8x
|
1.923 B
|
1.551 B
|
0.6%
|
66.5%
|
43.9
|
—
|
75.2%
|
